PGEN stock forecast, quote, news & analysis
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms... Show more
Why Precigen (PGEN) Is Down -5% in the Last 30 Days
Key Takeaways
- PGEN stock declined approximately -5% over the past 30 days amid volatility following Q4 2025 earnings, despite positive revenue growth from PAPZIMEOS launch.
- Over the past quarter, the stock is down around -24%, reflecting broader biotech sector pressures and post-earnings profit-taking after earlier highs.
- Main drivers include mixed earnings reaction with strong product revenue but large net losses from non-cash charges, ongoing commercialization momentum, and analyst optimism with targets above current levels.
- Volatility spiked with high trading volumes on down days, influenced by market sentiment in biotechnology stocks.
- PAPZIMEOS, the FDA-approved therapy for recurrent respiratory papillomatosis (RRP), generated $3.4 million in Q4 net product revenue, signaling commercial potential.
Precigen (PGEN) Company Overview and Market Position
Precigen, Inc. (PGEN) is a commercial-stage biopharmaceutical company focused on developing gene and cell therapies using its proprietary precision bioengineering platform. The company targets diseases with significant unmet needs, particularly in immuno-oncology, autoimmune disorders, and infectious diseases. Its core business model revolves around innovative platforms like AdenoVerse for gene delivery and UltraCAR-T for cell therapies.
In the competitive biotechnology industry, Precigen differentiates through its synthetic biology technologies, enabling off-the-shelf therapies. The recent FDA approval and launch of PAPZIMEOS (zopapogene imadenovec-drba), the first approved treatment for adults with recurrent respiratory papillomatosis (RRP), marks its transition to commercial-stage operations. This positions Precigen favorably in niche markets, though it faces typical biotech challenges like clinical risks and funding needs. Strong fundamentals from PAPZIMEOS revenue growth help explain resilience amid recent stock price pressure.
Precigen (PGEN) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, PGEN stock has declined by approximately -5%, closing around $3.25 recently after fluctuating between $3.10 and $3.89. The movement has been volatile, with a sharp -11.44% drop on March 30 amid high volume of over 13 million shares, following peaks near $3.89 earlier in the period. This reflects range-bound trading post-earnings, down from around $3.42 thirty days prior.
For the past quarter, the stock is down about -24%, trading from highs near $4.28 in early January to current levels near $3.25. Performance has been trend-driven downward after February peaks up to $5.47 (52-week high), with increased volatility tied to earnings and sector trends. Volume spikes, such as 23.5 million shares on March 26, underscore event-driven swings.
What Drove PGEN Stock Price in the Last 30 Days
The primary catalyst was the March 25 release of Q4 and full-year 2025 earnings, showing total revenue of $9.7 million (up 149% YoY) driven by $3.4 million in PAPZIMEOS net product revenue from its initial partial quarter of U.S. sales. Management guided for Q1 2026 revenue exceeding $18 million, highlighting strong demand and payer coverage for over 90% of U.S. insured lives. However, a $429.6 million net loss ($1.37 per share), largely from non-cash warrant charges, led to a mixed reaction with initial gains followed by profit-taking and a sharp drop.
Analyst updates supported sentiment, with Citizens JMP maintaining Market Outperform and raising the target to $9. Positive expert consensus naming PAPZIMEOS as first-line standard-of-care bolstered commercialization narrative. Yet, biotech sector weakness and high short interest amplified downside volatility. No major downgrades occurred, but profit-taking after a 132% 1-year gain contributed to the decline.
What Drove PGEN Stock Performance Over the Last Quarter
The quarter's -24% decline followed earlier momentum from PAPZIMEOS FDA approval in August 2025 and launch, peaking at $5.47 in February. Cumulative impacts included sustained commercialization efforts, with SG&A expenses up 70% for sales force expansion, offset by R&D cuts. Revenue ramp-up to $9.7 million annually validated the platform but was overshadowed by net losses and non-cash hits.
Macro factors like biotech market rotation amid rising rates pressured small-caps, while institutional buying earlier supported highs. Pipeline updates on UltraCAR-T and AdenoVerse platforms added long-term appeal, but competitive positioning in gene therapy faced regulatory and efficacy scrutiny. Overall, post-launch enthusiasm faded into volatility as investors weighed execution risks against growth.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the top-performing AI trading bots from its extensive library of hundreds of algorithms actively trading thousands of tickers across various markets. This curated section highlights bots with the strongest recent performance, relevance to current market trends, and diverse strategies such as trend-following, mean reversion, scalping, or momentum plays. Each bot displays key metrics like win rate, average return, Sharpe ratio (a measure of risk-adjusted performance), and timeframe suitability, from intraday to long-term positions. Updated in real-time, the page helps traders identify tools aligned with their risk tolerance and goals. Explore Trending AI Robots to enhance your trading with data-driven automation.
PGEN Stock Forecast Drivers: What Investors Should Watch Next
Investors should monitor Q1 2026 earnings in May for confirmation of over $18 million revenue guidance from PAPZIMEOS, including uptake post-permanent J-code (J3404) effective April 1. Track EMA review of Marketing Authorization Application for European expansion and progress in open-label redosing study for RRP retreatment efficacy.
Industry trends in gene therapy and RRP treatment adoption, plus macroeconomic factors like interest rates impacting biotech funding, remain key. Strategic developments such as pediatric RRP trials and UltraCAR-T pipeline (e.g., PRGN-3005) could influence sentiment. Risks include commercialization execution, competition, and regulatory hurdles; catalysts may arise from payer expansions or partnerships.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
PGEN in upward trend: 10-day moving average moved above 50-day moving average on June 17, 2026
The 10-day moving average for PGEN crossed bullishly above the 50-day moving average on June 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on June 11, 2026. You may want to consider a long position or call options on PGEN as a result. In of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for PGEN just turned positive on June 12, 2026. Looking at past instances where PGEN's MACD turned positive, the stock continued to rise in of 51 cases over the following month. The odds of a continued upward trend are .
PGEN moved above its 50-day moving average on June 11, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where PGEN advanced for three days, in of 229 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for PGEN moved out of overbought territory on July 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 63 cases where PGEN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PGEN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
PGEN broke above its upper Bollinger Band on June 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for PGEN entered a downward trend on June 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (95.238) is normal, around the industry mean (21.001). P/E Ratio (0.000) is within average values for comparable stocks, (36.006). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.690). PGEN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (55.866) is also within normal values, averaging (368.009).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company, which engages in the research and development of synthetic biology technologies.
Industry Biotechnology